Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2012 | 02:29pm CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Stephen Rea

+44 (0) 20 8047 5502

(London)

Sarah Spencer

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+ 44 (0) 20 8047 5503

(London)

James Dodwell

+ 44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 GLAXOSMITHKLINE : *jefferies raises glaxosmithkline price target to 1800 pence -..
02/16 ASTRAZENECA : Milan mayor sees EU picking new home for drugs agency by June
02/16DJVECTURA : Hits GBP9 Million Royalty Target on Glaxo's Ellipta Products
02/16 Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal
02/14 Gilead challenges GSK with strong HIV drug data
02/14 GLAXOSMITHKLINE : ViiV Gets Encouraging HIV Treatment Trial Results
02/14 GLAXOSMITHKLINE : ViiV Healthcare announces detailed positive phase III results ..
02/13 GLAXOSMITHKLINE : *jpmorgan raises glaxosmithkline price target to 1670 pence - ..
02/10 GILEAD SCIENCES, INC. (NASDAQ : GILD), GlaxoSmithKline Plc (NYSE:GSK) Battle Hea..
More news
Sector news : Pharmaceuticals - NEC
01:23pDJBAYER : Trump Backing for Bayer's Monsanto Deal Buoys Investors
01:06pDJBAYER : 4Q 2016 -- Forecast
08:25aDJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/17 What Makes Amgen A Compelling Buy In 2017?
02/17 Take The Road Less Traveled
02/16 Can Axovant Sciences Deliver In 2017?
02/15 Gilead And Glaxo's HIV Battle Intensifies
02/14 Gilead Will Free-Fall In Spite Of Carl Icahn
Advertisement
Financials ( GBP)
Sales 2017 29 948 M
EBIT 2017 8 405 M
Net income 2017 4 175 M
Debt 2017 13 565 M
Yield 2017 4,88%
P/E ratio 2017 20,29
P/E ratio 2018 17,01
EV / Sales 2017 3,14x
EV / Sales 2018 3,01x
Capitalization 80 506 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 17,7  GBP
Spread / Average Target 7,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC4.96%99 883
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results